Nimbus Therapeutics’ 2016 deal with Gilead Sciences, which is worth up to $1.2 billion for a MASH-related program, left some wondering if the win would be a fluke.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,